Nov18: In people with type 1 diabetes, the immune system mistakenly identifies insulin-producing cells in the pancreas as foreign and attacks them, leaving the body unable to properly regulate blood sugar. While insulin therapy helps manage the disease, it does not stop the underlying immune attack.
Now, UCLA researchers have identified a potential new way to protect these cells by harnessing extracellular vesicles — tiny particles naturally released by nearly all types of cells that help them communicate with one another.
In a study published in Nature Nanotechnology, the team found that vesicles produced by certain types of stem cells can help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in mice. The findings suggest a possible strategy for preserving insulin-producing cells before they are destroyed.
Harnessing stem cells' natural ability to regulate immunity
The research was inspired in part by a remarkable feature of pregnancy: A mother's immune system generally tolerates a developing embryo, even though it carries genetic material from the father that her immune system could recognize as foreign.
"Nature has designed something amazing," said senior author Song Li, associate dean for graduate and professional education and a professor of bioengineering at the UCLA Samueli School of Engineering and a member of the UCLA Broad Stem Cell Research Center. "If we can better understand how an embryo avoids rejection by the mother's immune system, it could be very useful for a lot of immune-related diseases."
With that idea in mind, Li's team investigated whether extracellular vesicles released by pluripotent stem cells — which share characteristics with cells found in early embryonic development — might also possess immune-regulating properties.
The researchers compared vesicles from embryonic stem cells and induced pluripotent stem cells, or iPSCs, with those from mesenchymal stem cells, which have been widely studied for their ability to regulate inflammation.
In experiments using mouse and human immune cells, vesicles from both types of pluripotent stem cells showed stronger anti-inflammatory effects than those from mesenchymal stem cells. They also promoted the formation of regulatory T cells, specialized immune cells that help prevent the immune system from attacking the body's own tissues.
Further analysis showed that the vesicles carry distinctive proteins, lipids and genetic material that may contribute to their immune-regulating properties, providing insight into how these naturally produced nanoparticles influence immune cells.
Protecting insulin-producing cells
To test whether these immune-regulating effects could help prevent diabetes, the researchers introduced immune cells that attack insulin-producing pancreatic cells into mice, then treated the animals with extracellular vesicles derived from iPSCs.
Because extracellular vesicles are rapidly cleared from the injection site, the team developed an injectable hydrogel that gradually releases them over several days.
The treatment was injected beneath the skin near the neck, where the vesicles could interact with immune cells in nearby lymph nodes. These immune cells could then circulate throughout the body, potentially reducing harmful immune activity in the pancreas.
The researchers found that two treatments with extracellular vesicles, either alone or delivered through the hydrogel, significantly delayed the onset of diabetes compared with untreated controls. At the end of the 90-day study, 55% of mice receiving vesicles in the hydrogel remained diabetes-free.
Mice receiving vesicles in the hydrogel also had more regulatory T cells in their lymph nodes and retained more insulin-producing pancreatic tissue than control animals.
"One thing that surprised us was that a local injection could provide protection throughout the body," said Li, who is also a member of the UCLA Health Jonsson Comprehensive Cancer Center and the California NanoSystems Institute at UCLA. "That's the beauty of this approach."
Making enough particles for future therapies
The researchers also addressed a major obstacle to developing extracellular vesicle-based treatments: producing sufficient quantities of consistent, high-quality particles.
Rather than growing stem cells on flat laboratory surfaces, the team grew them in three-dimensional clusters suspended in gently moving liquid. This approach increased vesicle production 3.4-fold per million cells while preserving important characteristics of the particles.
Stem cells grown in 3D clusters suspended in gently moving liquid (right panel) produced significantly more extracellular vesicles than stem cells grown flat in a lab dish (left panel) | Credit: Jana Zárubová, Li Lab
Because iPSCs can multiply extensively in the laboratory, they could provide a more consistent and scalable source of therapeutic vesicles than adult stem cells, whose growth potential is more limited.
The approach remains experimental, and further studies are needed to determine whether it would be safe and effective in people.
Li envisions the greatest potential for patients in earlier stages of type 1 diabetes, when some insulin-producing cells remain functional.
"In the early stages, you still have some pancreatic cells left," Li said. "If you can regulate the immune cells, you may be able to keep the remaining cells functional."
In more advanced disease, immune regulation alone would not replace cells that have already been lost. However, the approach could potentially help prevent immune rejection of transplanted insulin-producing cells.
The team hopes to test the approach in larger animal models and investigate appropriate dosing, long-term effectiveness and whether the treatment could weaken the body's defenses against infection.
Beyond diabetes, the findings could inform research into other autoimmune diseases and strategies for protecting transplanted cells from immune rejection.

